Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Systemic sclerosis

Autologous HSCT is efficacious, but can we make it safer?

Autologous haematopoietic stem cell transplantation (HSCT) has proved efficacious in treating patients with systemic sclerosis, but different regimens have different associated toxicities and different effects on lung function. Through comparison of different clinical trials, we can learn how to improve the safety of HSCT.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sullivan, K. M. et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N. Engl. J. Med. 378, 35–47 (2018).

    Article  Google Scholar 

  2. van Laar, J. M. et al. Autologous hematopoietic stem cell transplantation versus intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311, 2490–2498 (2014).

    Article  CAS  Google Scholar 

  3. Burt, R. K. et al. Aurtologous non-myeloablative haematopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomized phase II study. Lancet 378, 498–506 (2011).

    Article  CAS  Google Scholar 

  4. Burt, R. K. et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 381, 1116–1124 (2013).

    Article  Google Scholar 

  5. Burt, R. K., Oliveira, M. C. & Shah, S. J. Cardiac assessment before stem cell transplantation for systemic sclerosis. JAMA 312, 1803 (2014).

    Article  Google Scholar 

  6. Burt, R. K. et al. Hematopoietic stem cell transplantation for systemic sclerosis: if you are confused, remember: “it is a matter of the heart”. J. Rheumatol. 39, 206–209 (2012).

    Article  CAS  Google Scholar 

  7. Farge, D. et al. Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transplant. 52, 1495–1503 (2017).

    Article  CAS  Google Scholar 

  8. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02516124 (2017).

  9. Snowden, J. A. et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv. 1, 2742–2755 (2017).

    Article  Google Scholar 

  10. Farge, D. et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 95, 284–292 (2010).

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to dedicate this manuscript to the memory of Walter Barr, Professor of Rheumatology at Northwestern University, Chicago, IL, USA (1949–2008). The authors would also like to thank John A. Snowden at the Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK for review of the manuscript and for constructive comments.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Richard K. Burt.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information S1 (table)

Comparison of ASSIST, ASTIS and SCOT trials. (PDF 138 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Burt, R., Farge, D. Autologous HSCT is efficacious, but can we make it safer?. Nat Rev Rheumatol 14, 189–191 (2018). https://doi.org/10.1038/nrrheum.2018.34

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2018.34

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing